BGM Group Ltd.
Business
BGM Group Ltd is a Cayman Islands holding company that conducts its business operations in China through contractual arrangements with Gansu Qilianshan Pharmaceutical Co., Ltd. Main products include oxytetracycline APIs and tablets, licorice extracts and Gan Di Xin®, Ahan® antibacterial paste, heparin sodium preparations, natural sausage casings and organic and organic‑inorganic fertilizers. Key business segments comprise the WFOE (Qilian International Trading (Chengdu)), the VIE Gansu QLS and its subsidiaries (including Ahan, Chengdu QLS and Moshangfa) and strategic technology and biopharmaceutical initiatives. Products are manufactured in China and sold through qualified distributors, dealers and corporate customers across more than 20 provinces in China.
Summary from filing dated 2025-01-27
Financials
Latest annual snapshot (FY2024, period end 2024-09-30). Full statement history unavailable for this entity.
| Revenue | $25.10M |
| Net income | $-1.44M |
| Total assets | $53.00M |
| Total liabilities | $8.91M |
| Stockholders' equity | $42.74M |
| Operating cash flow | $544.2K |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is BGM Group Ltd.'s CIK number?
BGM Group Ltd.'s SEC CIK number is 0001779578 (1779578). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find BGM Group Ltd.'s SEC filings?
All of BGM Group Ltd.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.